Neurological adverse events associated with antipsychotic treatment in children and adolescents

Journal of Child Neurology

Volumn 23, Issue 12, 2008, Pages 1392-1399

  Jerrell, Jeanette M ^a   Hwang, Te Long ^a   Livingston, Timothy S ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressants; Antipsychotics; Neurological adverse events

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CENTRAL STIMULANT AGENT; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; FLUPHENAZINE; FLUVOXAMINE; HALOPERIDOL; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; ZIPRASIDONE;

ADOLESCENT; ARTICLE; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; CONVULSION; DRUG MEGADOSE; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HIGH RISK PATIENT; HUMAN; INFANT; INVOLUNTARY MOVEMENT; MAJOR CLINICAL STUDY; MALE; MEDICAID; MENTAL DEFICIENCY; MENTAL DISEASE; MONOTHERAPY; MOTOR DYSFUNCTION; MYOCLONUS; NEUROLEPTIC MALIGNANT SYNDROME; NEUROTOXICITY; OROFACIAL DYSKINESIA; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEDATION; SEIZURE; SEROTONIN SYNDROME; SIDE EFFECT; SOMNOLENCE; STIFF MAN SYNDROME; TARDIVE DYSKINESIA; TORSION DYSTONIA; TREMOR;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; CHILD; COHORT STUDIES; CONFIDENCE INTERVALS; DATABASES, FACTUAL; FEMALE; HUMANS; MALE; MENTAL DISORDERS; NERVOUS SYSTEM DISEASES; ODDS RATIO; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 57749186408     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/0883073808319070     Document Type: Article

References (24)

1. Findling RL, Steiner H., Weller EB Use of antipsychotics in children and adolescents. J Clin Psychiatry. 2005;66 (Suppl 7):29-40.
2. Patel NC, Crismon ML, Hoagwood K., Jensen P. Unanswered questions regarding atypical antipsychotic use in aggressive children and adolescents. J Child Adolesc Psychopharm. 2005;15:270-284.
3. Zito JM, Safer DJ, dosReis S., et al. Psychotropic practice patterns for youth: A 10-year perspective. Arch Pediatr Adolesc Med. 2003;157:17-25.
4. Cheng-Shannon J., McGough JJ, Pataki C., McCracken JT Second generation antipsychotic medications in children and adolescents. J Child Adolesc Psychopharm. 2004;14:372-394.
5. Toren P., Ratner S., Laor N., Weizman A. Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents. Drug Safety. 2004;27:1135-1156.
6. Jensen PS, Buitelaar J., Pandina GJ, Binder C., Haas M. Management of psychiatric disorders in children and adolescents with atypical antipsychotics. Eur Child Adolesc Psychiatry. 2007;16:104-120.
7. Masi G., Mucci M., Pari C. Children with schizophrenia: Clinical picture and pharmacological treatment. CSN Drugs. 2006;20:841-866.
8. McConville BJ, Sorter MT Treatment challenges and safety considerations for antipsychotic use in children and adolescents with psychoses. J Clin Psychiatry. 2004;65(Suppl 6):20-29.
9. Stigler KA, Potenza MN, McDougle CJ Tolerability profile of atypical antipsychotics in children and adolescents. Paediatr Drugs. 2001;3:927-942.
10. Ananth J., Parameswaran S., Gunatilake S. Side effects of atypical antipsychotic drugs. Curr Pharm Des. 2004;10:2219-2229.
11. McIntyre RS, Konarski JZ Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder. J Clin Psychiatry 2005;66 (Suppl 3):28-36.
12. Sikich L., Hamer RM, Bashford RA, Sheitman BB, Lieberman JA A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: A double-blind, randomized, 8-week trial. Neuropsychopharmacology. 2004;29:133-145.
13. Correll CU, Leucht S., Kane JM Lower risk for tardive dyskinesia associated with second generation antipsychotics: A systematic review of 1-year studies. Am J Psychiatry. 2004;161:414-425.
14. Ellsworth AJ, Witt DM, Dugdale DC, Oliver L. Mosby's Medical Drug Reference. St. Louis, MO: Mosby; 2006.
15. Correll CU, Penzner JB, Parikh UH, et al: Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child Adolesc Psychiatric Clin N Am 2006;15:177-206.
16. Wagner KD, Weller EB, Carlson GA, et al. An open-label trial of divalproex in children and adolescents with bipolar disorder. J Am Acad Child Adol Psychiatry 2002;41:1224-1230.
17. Rodnitzky RL Drug-induced movement disorders in children. Semin Pediatr Neurol. 2003; 10(1): 80-87.
18. Addonizio G., Roth SD, Stokes PE, Stoll PM Increased extrapyramidal symptoms with addition of lithium to neuroleptics. J Nerv Ment Dis. 1988;176:682-685.
19. Devane CL, Sallee FR SSRIs in child and adolescent psychiatry: A review of published experience. J Clin Psychiatry. 1996;57:55-66.
20. Magulac M., Landsverk J., Golshan S., Jeste DV Abnormal movements in neuroleptic-naïve children and adolescents. Can J Psychiatry. 1999;44:368-373.
21. Sokolski KN, Chicz-Demet A., Demet EM Selective serotonin reuptake inhibitor-related extrapyramidal symptoms in autistic children: A case series. J Child Adolesc Psychopharmacol. 2004;14:143-147.
22. Velamoor VR Neuroleptic malignant syndrome: Recognition, prevention, and management. Drug Safety Concept. 1998; 19: 73-82.
23. Coulter DM, Pillans PI Fluoxetine and extrapyramidal side effects. Am J Psychiatry. 1995;152:122-125.
24. Skowron DM, Stimmel GL Antidepressants and the risk of seizures. Pharmacotherapy. 1992;12:18-22.